Guideline No. 410: Prevention, Screening, Diagnosis, and Pregnancy Management for Fetal Neural Tube Defects

被引:24
|
作者
Wilson, R. Douglas
Van Mieghem, Tim
Langlois, Sylvie
Church, Paige
机构
[1] Calgary, AB
[2] Toronto, ON
[3] Vancouver, BC
关键词
spina bifida; neural tube defects; myelomeningocele; prenatal diagnosis; fetal surgery; neural tube defect prevention; neural tube defect screening; neural tube defect diagnosis; neural tube defect management; OPEN SPINA-BIFIDA; MATERNAL RISK-FACTORS; QUALITY-OF-LIFE; PRENATAL-DIAGNOSIS; FOLIC-ACID; CESAREAN-SECTION; INTRACRANIAL TRANSLUCENCY; FETOSCOPIC SURGERY; 1ST TRIMESTER; YOUNG-PEOPLE;
D O I
10.1016/j.jogc.2020.11.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: This revised guideline is intended to provide an update on the genetic aspects, prevention, screening, diagnosis, and management of fetal neural tube defects. Target population: Women who are pregnant or may become pregnant. Neural tube defect screening should be offered to all pregnant women. Options: For prevention: a folate-rich diet, and folic acid and vitamin B12 supplementation, with dosage depending on risk level. For screening: second-trimester anatomical sonography; first-trimester sonographic screening; maternal serum alpha fetoprotein; prenatal magnetic resonance imaging. For genetic testing: diagnostic amniocentesis with chromosomal microarray and amniotic fluid alpha fetoprotein and acetylcholinesterase; fetal exome sequencing. For pregnancy management: prenatal surgical repair; postnatal surgical repair; pregnancy termination with autopsy. For subsequent pregnancies: prevention and screening options and counselling. Outcomes: The research on and implementation of fetal surgery for prenatally diagnosed myelomeningocele has added a significant treatment option to the previous options (postnatal repair or pregnancy termination), but this new option carries an increased risk of maternal morbidity. Significant improvements in health and quality of life, both for the mother and the infant, have been shown to result from the prevention, screening, diagnosis, and treatment of fetal neural tube defects. Benefits, harms, and costs: The benefits for patient autonomy and decision-making are provided in the guideline. Harms include an unexpected fetal diagnosis and the subsequent management decisions. Harm can also result if the patient declines routine sonographic scans or if counselling and access to care for neural tube defects are delayed. Cost analysis (personal, family, health care) is not within the scope of this clinical practice guideline. Evidence: A directed and focused literature review was conducted using the search terms spina bifida, neural tube defect, myelomeningocele, prenatal diagnosis, fetal surgery, neural tube defect prevention, neural tube defect screening, neural tube defect diagnosis, and neural tube defect management in order to update and revise this guideline. A peer review process was used for content validation and clarity, with appropriate ethical considerations. Validation Methods: The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and weak recommendations). Intended Audience: Maternity care professionals who provide any part of pre-conception, antenatal, delivery, and neonatal care. This guideline is also appropriate for patient education.
引用
收藏
页码:124 / +
页数:24
相关论文
共 50 条
  • [41] Prevalence of Neural Tube Defects and the Impact of Prenatal Diagnosis in Three Districts of Beijing, China
    Jin, Lei
    Jin, Lei
    Yu, Jingru
    Xu, Yanjun
    Liu, Hui
    Ren, Aiguo
    PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2017, 31 (04) : 293 - 300
  • [42] Guideline No. 439: Diagnosis and Management of Vasa Previa
    Jain, Venu
    Gagnon, Robert
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2023, 45 (07) : 506 - 518
  • [43] Folate and prevention of neural tube defects
    Clarke, Robert
    Bennett, Derrick
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [44] Prevalence of neural tube defects in northeastern France, 1979-1994 impact of prenatal diagnosis
    Alembik, Y
    Dott, B
    Roth, MP
    Stoll, C
    ANNALES DE GENETIQUE, 1997, 40 (02): : 69 - 71
  • [45] Effects of folic acid supplementation during different pregnancy periods and relationship with the other primary prevention measures to neural tube defects
    Gong, Rui
    Wang, Zhi-Ping
    Wang, Meng
    Gao, Li-Jie
    Zhao, Zhong-Tang
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2016, 29 (23) : 3894 - 3901
  • [46] Fetal Pathology of Neural Tube Defects - An Overview of 68 Cases
    Schoner, Katharina
    Axt-Fliedner, Roland
    Bald, Rainer
    Fritz, Barbara
    Kohlhase, Juergen
    Kohl, Thomas
    Rehder, Helga
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2017, 77 (05) : 495 - 507
  • [47] Folic acid: Primary prevention of neural tube defects. Literature Review
    Llamas Centeno, Maria Jose
    Miguelez Lago, Carlos
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (02): : 73 - 85
  • [48] Neural tube defects: Knowledge and preconceptional prevention practices in minority young women
    Chacko, MR
    Anding, R
    Kozinetz, CA
    Grover, JL
    Smith, PB
    PEDIATRICS, 2003, 112 (03) : 536 - 542
  • [49] The outcome and course of pregnancies complicated with fetal neural tube defects
    Steric, M.
    Stamenkovic, J. Dukanac
    Srbinovic, L.
    Janjic, T.
    Petronijevic, S. Vrzic
    Petronijevic, M.
    Cetkovici, A.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2015, 42 (01) : 57 - 61
  • [50] Second trimester maternal serum screening for fetal open neural tube defects and aneuploidy
    Driscoll, DA
    GENETICS IN MEDICINE, 2004, 6 (06) : 540 - 541